Clinical Trial Update: GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease [Phase 1]

View source ↗

Summary

GRAVITAS-119, a Phase 1 study evaluating itacitinib with calcineurin inhibitor-based interventions for prophylaxis of graft-versus-host disease in hematologic m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• Itacitinib (itacitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Hematologic Malignancies | Phase 1 | Status: TERMINATED